Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion, highlighting the company's broader pipeline expansion strategy.

Johnson Fistel, PLLP is investigating whether Evotec SE complied with federal securities laws following the company's announcement of its 'Horizon' restructuring initiative on March 10, 2026. The investigation focuses on potential investor losses related to Evotec's financial guidance projecting €700-780 million in revenue and €0-40 million in adjusted EBITDA for fiscal year 2026, along with €100 million in restructuring charges expected over 2026-2028.

The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.

Amgen acquired Dark Blue Therapeutics for up to $840 million to strengthen its oncology pipeline. Dark Blue's lead candidate DBT 3757 targets acute myeloid leukemia and acute lymphoblastic leukemia. The acquisition complements Amgen's targeted protein degradation research and advances its early-stage cancer medicine strategy.

MUVON Therapeutics announced positive Phase 2 clinical trial results for a novel muscle precursor cell therapy treating stress urinary incontinence, demonstrating high statistical significance and an 87% responder rate. The company also appointed Dr. Christine Günther as Chief Technology Officer to advance their regenerative medicine platform.

The global antibody discovery market is projected to grow from USD 8.42 billion in 2024 to USD 17.68 billion by 2032, driven by increasing demand for targeted therapies and advancements in biologics for treating chronic diseases like cancer and autoimmune disorders.

The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.

Kazia Therapeutics reported a patient with stage IV triple-negative breast cancer achieved an initial immune-complete response when treated with paxalisib combined with pembrolizumab and standard chemotherapy, showing a profound radiologic response in a highly aggressive cancer subtype.

Kazia Therapeutics plans to request an FDA meeting to discuss overall survival data for paxalisib, a potential treatment for glioblastoma, aiming to pursue conditional approval under the FDA's Project FrontRunner initiative.

Kazia Therapeutics reported an 86% reduction in tumor burden for a metastatic triple-negative breast cancer patient using a combination of paxalisib, immunotherapy, and chemotherapy in an expanded-access case.

The global pharmaceutical contract research organization (CRO) services market is projected to grow at a 10% CAGR, reaching USD 25 billion by 2035, driven by increasing outsourcing trends in drug discovery and development across North America and Europe.

The global drug discovery platforms market is projected to grow from $186.24 million in 2024 to $635.45 million by 2034, driven by AI, technological advancements, and increased pharmaceutical R&D investments. North America leads the market, with Asia-Pacific expected to see the fastest growth.